ClinicalTrials.Veeva

Menu

Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study (Code Barre)

U

University Hospital, Rouen

Status

Completed

Conditions

Stage II and III
Colorectal Cancer

Treatments

Genetic: evaluation of the recurrence rate according to molecular analysis

Study type

Interventional

Funder types

Other

Identifiers

NCT02110329
2007/040/HP

Details and patient eligibility

About

Lymph node involvement remains the main criteria for postoperative chemotherapy in patients with colon cancer (CC) without distant metastasis. To date, the prognostic value of the somatic quantitative molecular alterations such as loss or gain of genomic region is not established in CC.

AIMS & METHODS: Using the one-step screening method based on the Quantitative Multiplex PCR of Short fluorescent Fragments (QMPSF), we aimed to assess the prognostic role of the simultaneous detection of main quantitative somatic alterations in stage II-III CC.

Patients and Methods. We enrolled and collected all baseline characteristics of patients operated for a stage II-III CC with storage frozen tissues. The QMPSF was based on a simultaneous amplification of 9 selected target genomic sequences from literature: DCC (18q21); EGFR (7p12); P53 (17p13.1); BLK (8p23-p22); c-myc (8q24.12); APC (5q22.2); ERBB2 (17q12); STK6 (20q13.31); NR21 (14p11.1) and two control: DCOHM (5q31.1); HMBS (11q23.3). Comparison of each amplicon electropherograms obtained from tumour vs normal peritumoral tissue allowed us to identified gain or loss genomic region. The primary end-point was the local and/or distant recurrence and relation between clinical and single or combined molecular alterations and recurrence were evaluated.

Enrollment

401 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age over 18
  • localized colon cancer
  • proven adenocarcinoma
  • surgery R0
  • no metastatic disease
  • stage II or III
  • WHO performance status 0, 1 or 2
  • availaible frozen tissue
  • written consent
  • no major co-morbidities

Exclusion criteria

  • metastatic disease
  • hereditary colorectal cancer
  • rectal cancer

Trial design

401 participants in 1 patient group

stage II-III colon cancer treated with surgery
No Intervention group
Description:
stage II-III colon cancer treated with surgery
Treatment:
Genetic: evaluation of the recurrence rate according to molecular analysis

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems